Celyad SA (CYAD)

Currency in EUR
0.39
-0.01(-2.53%)
Closed·
CYAD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CYAD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.360.40
52 wk Range
0.211.22
Key Statistics
Prev. Close
0.4
Open
0.4
Day's Range
0.36-0.4
52 wk Range
0.21-1.22
Volume
8.25K
Average Volume (3m)
31.44K
1-Year Change
67.71%
Book Value / Share
0.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CYAD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Celyad SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Celyad SA Company Profile

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Compare CYAD to Peers and Sector

Metrics to compare
CYAD
Peers
Sector
Relationship
P/E Ratio
−2.8x−3.6x−0.5x
PEG Ratio
−0.050.080.00
Price/Book
31.6x0.9x2.6x
Price / LTM Sales
86.9x8.7x3.3x
Upside (Analyst Target)
-84.7%43.5%
Fair Value Upside
Unlock6.0%6.9%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CYAD Income Statement

People Also Watch

16.85
RBWR
+1.51%
4.2400
NB
+5.21%
211.82
RDDT
-0.47%
3.91
IRBT
-7.35%
10.500
CHPT
+5.53%

FAQ

What Stock Exchange Does Celyad Trade On?

Celyad is listed and trades on the Brussels Stock Exchange stock exchange.

What Is the Stock Symbol for Celyad?

The stock symbol for Celyad is "CYAD."

What Is the Celyad Market Cap?

As of today, Celyad market cap is 16.16M.

What Is Celyad's Earnings Per Share (TTM)?

The Celyad EPS (TTM) is -0.14.

When Is the Next Celyad Earnings Date?

Celyad will release its next earnings report on 24 Sept 2025.

From a Technical Analysis Perspective, Is CYAD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Celyad Stock Split?

Celyad has split 0 times.

How Many Employees Does Celyad Have?

Celyad has 18 employees.

What is the current trading status of Celyad (CYAD)?

As of 07 Aug 2025, Celyad (CYAD) is trading at a price of 0.39, with a previous close of 0.40. The stock has fluctuated within a day range of 0.36 to 0.40, while its 52-week range spans from 0.21 to 1.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.